InSite Vision Announces Positive Phase 1/2 Results for ISV-303 for the Reduction of Pain and Inflammation after Cataract Surgery.
Business Wire › March 22, 2011
Linked as:
Extract
InSite Vision Announces Positive Phase 1/2 Results for ISV-303 for the Reduction of Pain and Inflammation after Cataract Surgery.
Once-Daily ISV-303 Demonstrates Statistical Significance over Vehicle and Numeric Superiority over Twice-Daily Xibrom([TM])
InSite Vision's Late Stage Pipeline Now Includes Three Phase 3 Product Candidates ALAMEDA, Calif. -- InSite Vision Incorporated (OTCBB:INSV) today announced top-line results from its recently completed Phase 1/2 clinical trial of ISV-303, a topical anti-inflammatory product intended to reduce the pain and inflammation associated with ocular surgery. This rando...See the full content of this document
Sponsored links
